Sensitivity analyses showed that insulin pump therapy was most cost-effective in individuals with the highest baseline HbA1c, suggesting that CSII may represent a cost-effective therapeutic alternative for MDI-treated type 2 diabetes populations who have HbA1c levels above target [112]. Here, INS is linked to type 2 diabetes mellitus.